| Literature DB >> 28936478 |
Daniel Garcia1, Robert E Eilers1, S Brian Jiang1.
Abstract
BACKGROUND: Cutaneous melanoma is one of the fastest rising cancer diagnoses in recent years. Melanoma in situ (MIS) constitutes a large proportion of all diagnosed melanomas. While surgical excision is considered the standard of therapy, the literature is not clear on which surgical technique minimizes local recurrence. A common technique is serial staged excision (SSE), in which a series of mapped excisions are made according to histopathological examination of tissue. Previously published recurrence rates for SSE ranges from 0-12%, over a range of 4.7-97 months of mean follow-up.Entities:
Keywords: Dermatology; Excision; Lentigo maligna (LM); Malignant melanoma (MM); Melanoma in situ (MIS); Skin; Staged excision
Year: 2017 PMID: 28936478 PMCID: PMC5603294 DOI: 10.13188/2373-1044.1000037
Source DB: PubMed Journal: J Clin Investig Dermatol ISSN: 2373-1044
Figure 1Example of serial staged excision technique investigated.
Relationship of lesion size to number of stages required for clearance.
| Largest Diameter of Lesion | Number | Mean Surgical Margin | P-value |
|---|---|---|---|
| ≤5 mm | 2/29 | 8.5 mm | 0.1 |
| ≤10 mm | 10/29 | 11.1 mm | 0.13 |
| ≤20 mm | 22/29 | 13.7 mm | 0.2 |
| ≤30 mm | 25/29 | 13.8 mm | <0.01 |
| ≤40 mm | 26/29 | 13.7 mm | 0.01 |
| ≤50 mm | 27/29 | 13.4 mm | 0.04 |
Relationship of lesion size to number of stages required for clearance.
| Largest Diameter of Lesion | Number | Mean Number of Stages | P-value |
|---|---|---|---|
| ≤5 mm | 2/29 | 1 | 0.27 |
| ≤10 mm | 10/29 | 1.3 | 0.22 |
| ≤20 mm | 22/29 | 1.5 | 0.83 |
| ≤30 mm | 25/29 | 1.56 | 0.1 |
| ≤40 mm | 26/29 | 1.54 | 0.17 |
| ≤50 mm | 27/29 | 1.52 | 0.27 |
Literature review of serial staged excision for melanoma in situ.
| Staged Excision Studies | Recurrence | Time to Recurrence | Follow-up Duration |
|---|---|---|---|
| Walling et al. [ | 3/41 (7.3%) | 24 ± 13 months | 96 ± 43.6 |
| (range 60–240 months) | |||
| Bub et al. [ | 2/55 (3.6%) | Not reported | 57 months |
| (range 9–139 months) | |||
| Huilgol et al. [ | 2/125 (1.6%) | 12, 40 months | 38 ± 25 |
| Johnson et al. [ | 0/35 (0%) | NA | Not reported |
| Hill and Gramp. [ | 1/38 (2.6%) | 10 months | 25 months (range 10–48 months) |
| Anderson et al. [ | 1/150 (0.67%) | <5 years, not defined | Not reported |
| Agarwal-Antal et al. [ | 0/93 (0%) | Not reported | Not reported |
| “4 years after first patient” | |||
| Malhotra et al. [ | 4/109 (3.7%) | 12–40 months | 32±26 months |
| Mahoney et al. [ | 0/11 (0%) | NA | 4.7 months (range 1–13 months) |
| Jejurikar et al. [ | 0/51 (0%) | NA | 31 months (range 15–45 months) |
| Bosbous et al. [ | 1/59 (1.7%) | Not reported | 2.2 years (range 0–10.2 years) |
| Lee and Ryman [ | 3/31 (9.7%) | Mean 4 years | 42 months |
| Joyce et al. [ | 9/410 (2.2%) | Mean 29.6 months (range 8–47 months) | 23 months (range 1–65 months) |
| de Vries et al. [ | 4/100 (4%) | 37–77 months | Mean 60 months |
| Patel et al. [ | 1/21(4.76%) | 2 years | Not reported |
| Lawrence et al. [ | 4/56 (12%) | Mean 4.4 years (range 0.6–7.4 years) | Minimum 5 years (range 5–9.6 years) |
| Gaudy-Marqueste et al. [ | 0/20 (0%) | 48 months | Mean 25.36 months (range 0–72 months) |
| Möller et al. [ | 0/49 (0%) | NA | Median 14 months (range 1–36 months) |
| Garcia and Jiang | 0/29 (0%) | NA | Mean 31.5 months (range 12–58 months) |
Patient demographics and lesion characteristics.
| Serial Staged Excision for Melanoma | |
|---|---|
| Sex | Male 18/29 (64.7%), Female 11/29 (35.3%) |
| Age at Excision | Mean 72.2 years (SD 11.5) |
| Median 72 years (range 51–93) | |
| Fitzpatrick Skin Type | Type 1: 2/29 (6.8%) |
| Type 2: 26/29 (89.7%) | |
| Type 3: 1/29 (3.4%) | |
| Lesion Location | Head and Neck: 27/29 (93.1%) |
| Trunk and Extremities: 2/29 (6.8%) | |
| Preoperative Size 1 | Mean 13.6 mm (SD 12.1) |
| Preoperative Size 2 | Mean 13.4 mm (SD 9.3) |
| Final Surgical Margin | Mean 13.1 mm (SD 5.9) |
| Stages Needed for Histologically Clear Margins | Mean 1.48 stages (range 1–3) |
| Follow-up Duration | Mean 31.5 months (SD 13.9) |
| Median 30 months (range 12–58) | |
| Complications | 3/29 (10.3%); hematoma ×1, post-op bleeding ×2 |
| Recurrences | 0/29 (0%) |